An observational study in Hypoparathyroidism and Pseudohypoparathyroidism, sponsored by University Hospital Augsburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University Hospital Augsburg · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Chronic hypoparathyroidism is a rare condition in which the parathyroid glands do not make enough parathyroid hormone (PTH). PTH helps control the levels of calcium and phosphate in the blood. When there is not enough PTH, calcium levels can become too low and phosphate levels can become too high. This may cause symptoms such as tingling, muscle cramps, weakness, or other health problems.
The most common cause of chronic hypoparathyroidism is surgery in the neck area. It can happen after thyroid surgery, surgery on the parathyroid glands, or other operations in the neck.
At the moment, most patients are treated with calcium and vitamin D tablets. These treatments help control calcium levels, but they cannot fully replace the normal effects of PTH in the body. A medicine that contains a form of human PTH is available for some patients, but it is not yet the standard treatment for everyone.
This registry collects medical information and follows patients over time. Its aim is to better understand patients' symptoms, possible long-term health problems, treatments, and overall health. A group of patients who have had their thyroid removed but do not have hypoparathyroidism will also be included for comparison.
Chronic hypoparathyroidism is a rare endocrine disorder characterized by persistently reduced or absent secretion of parathyroid hormone (PTH), resulting in hypocalcemia and hyperphosphatemia with a broad spectrum of associated clinical manifestations. The most common etiology is postsurgical hypoparathyroidism, particularly following thyroid surgery, but it may also occur after parathyroid surgery or other surgical procedures involving the neck.
Hypoparathyroidism remains unique among endocrine deficiency disorders in that replacement of the deficient hormone has not yet become established as standard therapy. Although recombinant human PTH-based therapies are available for selected patient populations, conventional treatment currently relies primarily on oral calcium and vitamin D supplementation. While this approach can improve biochemical control, it does not fully reproduce the physiological actions of endogenous PTH and may therefore be associated with limitations in both short- and long-term disease management.
In Germany, systematic longitudinal data on patients with chronic hypoparathyroidism is limited. Therefore, this is a local registry for the structured documentation and follow-up of patients with chronic hypoparathyroidism and pseudohypoparathyroidism. The registry is intended to provide a structured basis for clinical, translational and basic research on chronic hypoparathyroidism. Key areas of investigation include the frequency, and severity of disease-related symptoms, diagnostic approaches and biochemical monitoring, organ specific effects, the effectiveness and limitations of conventional therapy and the emerging and novel therapeutic strategies, including PTH replacement therapies. Particular attention will also be given to long-term complications and associated comorbidities, treatment-related outcomes, quality of life and special life events like pregnancies.
Longitudinal follow-up will allow the clinical course of the disease, treatment requirements, and long-term outcomes to be assessed systematically. In addition, a cohort of patients who have undergone thyroidectomy without subsequent hypoparathyroidism will serve as a control group, allowing outcomes associated specifically with chronic hypoparathyroidism to be distinguished from those related to thyroid surgery and its underlying indications.
128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.
This study's planned enrollment of 150 is close to the median of 147 across 48 observational studies indexed under Hypoparathyroidism.
Browse Hypoparathyroidism studies →University Hospital Augsburg is the lead sponsor of 25 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients within the area of Augsburg and southern Germany
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Controll group
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
long-term comorbidities in hypoparathyroidism
compared with a controll group
Time frame: 15 years
Plan to share: Undecided — The data is available on reasonable request.
Started Jul 2021 (actual). Primary completion is estimated for Feb 2036, 174 months after the start.
Of 25 observational studies under Hypoparathyroidism, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 122. This study's planned 174 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Augsburg